Association between anlotinib trough plasma concentration and treatment outcomes in advanced non-small-cell lung cancer.
anlotinib
clinical efficacy
non-small cell lung cancer
toxicities
trough plasma concentration
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
17
01
2023
accepted:
20
02
2023
entrez:
20
3
2023
pubmed:
21
3
2023
medline:
21
3
2023
Statut:
epublish
Résumé
Efficacy and toxicities of anlotinib (ANL) show large inter-patient variation, which may partly be explained by differences in ANL exposure. Exposure-response/toxicities relationship have not been investigated for ANL. Therefore, the aim of the present study was to explore the association between the trough plasma concentration (C Patients with advanced NSCLC who started third-line or further ANL alone therapy between January 2021 and October 2022. This study examined the ANL C 52 patients were evaluated for analyses. The median ANL C Considering these results, we propose that maintaining ANL C
Sections du résumé
Background
UNASSIGNED
Efficacy and toxicities of anlotinib (ANL) show large inter-patient variation, which may partly be explained by differences in ANL exposure. Exposure-response/toxicities relationship have not been investigated for ANL. Therefore, the aim of the present study was to explore the association between the trough plasma concentration (C
Methods
UNASSIGNED
Patients with advanced NSCLC who started third-line or further ANL alone therapy between January 2021 and October 2022. This study examined the ANL C
Results
UNASSIGNED
52 patients were evaluated for analyses. The median ANL C
Conclusions
UNASSIGNED
Considering these results, we propose that maintaining ANL C
Identifiants
pubmed: 36937430
doi: 10.3389/fonc.2023.1146362
pmc: PMC10020721
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1146362Informations de copyright
Copyright © 2023 Chen, Jiang, Rao, Wang, Yan, Ye and Lou.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Chemother Pharmacol. 2020 Dec;86(6):803-813
pubmed: 33095285
JAMA Oncol. 2018 Nov 1;4(11):1569-1575
pubmed: 30098152
Int J Gynecol Cancer. 2018 Jan;28(1):152-160
pubmed: 28953502
Br J Cancer. 2018 Mar 6;118(5):654-661
pubmed: 29438373
Br J Clin Pharmacol. 2020 Feb;86(2):258-273
pubmed: 31782166
Basic Clin Pharmacol Toxicol. 2022 May;130(5):592-605
pubmed: 35289081
Clin Pharmacol Ther. 2017 Nov;102(5):765-776
pubmed: 28699160
Rapid Commun Mass Spectrom. 2021 Jan 15;35(1):e8955
pubmed: 32990383
Front Pharmacol. 2022 Jun 22;13:918219
pubmed: 35814206
Cancer Sci. 2018 Apr;109(4):1207-1219
pubmed: 29446853
Thorac Cancer. 2019 Mar;10(3):551-556
pubmed: 30666799
Drugs. 2018 Jul;78(10):1057-1062
pubmed: 29943374
Rapid Commun Mass Spectrom. 2022 Nov 15;36(21):e9372
pubmed: 35918299
Biomed Chromatogr. 2021 Dec;35(12):e5218
pubmed: 34291843
Br J Clin Pharmacol. 2017 Oct;83(10):2195-2204
pubmed: 28500677
J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Jun 15;1175:122752
pubmed: 33991955
Cancer Chemother Pharmacol. 2021 Aug;88(2):281-288
pubmed: 33928425
J Hematol Oncol. 2016 Oct 4;9(1):105
pubmed: 27716285
Acta Pharmacol Sin. 2018 Jun;39(6):1048-1063
pubmed: 29620050
Analyst. 2019 Sep 21;144(18):5462-5471
pubmed: 31380858
Cancer Biol Med. 2018 Nov;15(4):443-451
pubmed: 30766754
Biomed Res Int. 2017;2017:3619723
pubmed: 29441353
Biomed Chromatogr. 2022 Dec;36(12):e5501
pubmed: 36082703